.jetcityimage/iStock Editorial by means of Getty Images Morgan Stanley has picked Eli Lilly (NYSE: LLY) as its own best biopharma pick for 2025 and ranked yet another 9 titles in the space as overweight. The assets bank claimed in a keep in mind that it remains to feel “diabesity is readied to become.